ID   LIM2099
AC   CVCL_4436
SY   LIM 2099; LIM-2099
DR   BioSample; SAMN07624415
DR   cancercelllines; CVCL_4436
DR   CBA; CBA-0164
DR   ColonAtlas; LIM2099
DR   Cosmic; 1238053
DR   Cosmic; 1524326
DR   Cosmic; 1805260
DR   Cosmic; 2301993
DR   ECACC; 12062002
DR   GEO; GSM1346846
DR   GEO; GSM1448137
DR   Wikidata; Q54902530
RX   PubMed=1427983;
RX   PubMed=19378335;
RX   PubMed=24755471;
RX   PubMed=25926053;
CC   From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia.
CC   Doubling time: 36 hours (PubMed=1427983).
CC   Microsatellite instability: Stable (MSS) (PubMed=19378335; PubMed=24755471; PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=19378335; PubMed=24755471).
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
ST   Source(s): CBA=CBA-0164; PubMed=25926053
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 8
ST   D16S539: 11
ST   D18S51: 12,15
ST   D19S433: 13.2,14
ST   D21S11: 29,30
ST   D2S1338: 24,25
ST   D3S1358: 15
ST   D5S818: 11
ST   D7S820: 13
ST   D8S1179: 10,13
ST   FGA: 19,25
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 19
DI   NCIt; C5105; Colorectal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 27
//
RX   PubMed=1427983; DOI=10.1038/icb.1992.30;
RA   Whitehead R.H., Zhang H.H., Hayward I.P.;
RT   "Retention of tissue-specific phenotype in a panel of colon carcinoma
RT   cell lines: relationship to clinical correlates.";
RL   Immunol. Cell Biol. 70:227-236(1992).
//
RX   PubMed=19378335; DOI=10.1002/ijc.24289;
RA   Zhang H.-H., Walker F.E., Kiflemariam S., Whitehead R.H., Williams D.,
RA   Phillips W.A., Mikeska T., Dobrovic A., Burgess A.W.;
RT   "Selective inhibition of proliferation in colorectal carcinoma cell
RT   lines expressing mutant APC or activated B-Raf.";
RL   Int. J. Cancer 125:297-307(2009).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//